MC1R and metastatic melanoma: Recently, clinical trials are attempting to assess the effectiveness and safety of MC1R as a radiopharmaceutical target for metastatic melanoma.25,26 As with other targeted therapies, the efficacy of these agents relies on the expression of the target within the patient population affected by the disease.